Yes, there are several ongoing clinical trials aimed at targeting p53 in cancer therapy. These trials explore various approaches, including gene therapy to restore wild-type p53 function, small molecules that can reactivate mutant p53, and immunotherapy strategies to enhance the immune response against p53-mutant cancer cells. The outcomes of these trials could significantly impact future cancer treatments.
